Development and safety of investigational and approved drugs targeting the RAS function regulation in RAS mutant...

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• RAS proteins are key regulators of cellular functions, and their aberrant activation drives cancer development.
• Approved RAS inhibitors show significant antitumor activity but are limited by severe adverse reactions.
• Managing these side effects is essential for optimizing clinical application of RAS inhibitors.

Purpose of the Study:

• To review the evolution of RAS inhibitors in cancer therapy.
• To detail common adverse effects of RAS inhibitors and their mechanisms.
• To explore strategies for mitigating these adverse events and improving clinical safety.

Main Methods:

• Literature review of RAS inhibitors in cancer therapy.
• Analysis of reported adverse effects and their underlying biological mechanisms.
• Synthesis of current and potential management strategies for RAS inhibitor toxicities.

Main Results:

• RAS signaling pathways are critical in various cancers, making RAS inhibitors a target for treatment.
• Common adverse effects of RAS inhibitors include dermatologic, gastrointestinal, and cardiovascular toxicities.
• Understanding the mechanisms of toxicity is key to developing mitigation strategies.

Conclusions:

• Effective management of RAS inhibitor adverse events is necessary for their broader clinical adoption.
• Development of precise management guidelines, intermittent dosing, and novel combination regimens can enhance safety.
• Further research into mechanisms and mitigation strategies will improve the therapeutic index of RAS inhibitors.